Caitong International Asset Management’s Jyong Biotech MENS Stock Holding History

Caitong International Asset Management’s Portfolio MENS Stock Details MENS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19	Buy	+9	New	+$19	﹤0.01%	2535

Other funds holding MENS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Caitong International Asset Management's MENS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Jyong Biotech (MENS) in Q2 2026: 9 shares worth $19. The stake represents ﹤0.01% of the portfolio and ranks #2535 among its holdings.

19 funds tracked by Wall St. Rank hold MENS as of Q2 2026.

Caitong International Asset Management held 9 shares of Jyong Biotech worth $19 as of Q2 2026.
Jyong Biotech was a new Caitong International Asset Management position in Q2 2026.
Jyong Biotech made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2535 holding.
19 funds tracked by Wall St. Rank held Jyong Biotech as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.